Synairgen has selected Ennov PV to support the conduct of a clinical trial of SNG001 in patients with COVID-19. Synairgen will be using the Ennov PV Works solution to collect, manage and report clinical safety data associated with the trial.
“With COVID-19 impacting so many people around the world, Ennov is delighted to be able to continue supporting Synairgen in this important study” Says Nic Pillinger, Ennov Pharmacovigilance Director. “Our aim is to deliver reliable pharmacovigilance tools and services that allow the experts to focus their efforts on such important work.”
Ennov provides the most intuitive, comprehensive, and cost-effective suite of software solutions for the life sciences industry. From leading pharmaceutical companies to emerging biotechnology companies, we proudly serve over 200 companies and 150,000 users around the world. Our solutions are designed and built to support the entire Life Sciences R&D continuum including Clinical, Regulatory, Quality, Pharmacovigilance and Commercial. Ennov is headquartered in Paris and has offices in the US and UK. For more information about Ennov, please see www.ennov.com .
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defense in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.
Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients initiated in hospital and 120 patients to be initiated in the home setting. Synairgen announced positive preliminary results from the hospital setting on 20 July 2020.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com